DIC with Active Bleeding or at High Risk of Bleeding
Clinical Scenario
This protocol addresses disseminated intravascular coagulation in patients who are actively bleeding or who face a significantly elevated bleeding risk — including those recovering from surgery and those who need to undergo an invasive procedure. The clinical picture, not laboratory findings alone, drives management decisions in this setting.
Treatment Approach
When DIC is accompanied by active bleeding or elevated procedural risk, management centres on targeted blood product support guided by the patient's current platelet count and coagulation studies. Specific blood components are considered when defined clinical thresholds are met.
The complete decision criteria, component selection, and sequencing are in the full structured protocol below.
References
DOI: 10.1111/j.1365-2141.2009.07600.x
- Transfusion of platelets or plasma (components) in patients with DIC should not primarily be based on laboratory results and should in general be reserved for patients that present with bleeding (Grade C, Level IV).
- In patients with DIC and bleeding or at high risk of bleeding (e.g. postoperative patients or patients due to undergo an invasive procedure) and a platelet count of <50 × 10⁹/l, transfusion of platelets should be considered (Grade C, Level IV).
- In bleeding patients with DIC and prolonged PT and aPTT administration of FFP may be useful.
- It should not however be instituted based on laboratory tests alone but should be considered in those with active bleeding and in those requiring an invasive procedure.
View source ↗